NCT01243151

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational drug that is currently being studied as a lipid lowering agent.

Conditions

• Hypercholesterolemia
• Dyslipidemia

Interventions

Type	Name	Description
BIOLOGICAL	PF-04950615 (RN316)	Infusion every week
BIOLOGICAL	PF-04950615 (RN316)	Infusion every week
BIOLOGICAL	PF-04950615 (RN316)	Infusion every week
BIOLOGICAL	PF-04950615 (RN316)	Infusion every week
BIOLOGICAL	PF-04950615 (RN316)	Infusion every week

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2010-11-18
• Last updated: 2019-01-22
• Results posted: 2019-01-22

Locations

9 sites across 1 country: United States